- Home
- HBNC vs GOSS Comparison
HBNC vs GOSS Comparison
Compare HBNC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | GOSS |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 726.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HBNC | GOSS |
|---|---|---|
| Price | $17.29 | $3.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $19.67 | $8.60 |
| AVG Volume (30 Days) | 236.6K | ★ 2.9M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $44,051,000.00 |
| Revenue This Year | $51.78 | N/A |
| Revenue Next Year | $7.40 | $16.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.91 | N/A |
| 52 Week Low | $12.70 | $0.67 |
| 52 Week High | $18.54 | $3.60 |
Technical Indicators
Market Signals| Indicator | HBNC | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 62.17 |
| Support Level | $16.95 | $2.98 |
| Resistance Level | $17.61 | $3.45 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 85.08 | 85.55 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.